GC
ABMD

Grimes & Company’s Abiomed Inc ABMD Stock Holding History

Grimes & Company’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,014
Closed -$249K – 308
2022
Q3 		$249K Buy
+1,014
New +$274K 0.01% 236
2022
Q2 		– Sell
-614
Closed -$203K – 310
2022
Q1 		$203K Hold
614
– – 0.01% 284
2021
Q4 		$221K Sell
614
-60
-9% -$20.3K 0.01% 279
2021
Q3 		$219K Hold
674
– – 0.01% 274
2021
Q2 		$210K Buy
+674
New +$207K 0.01% 285

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Grimes & Company's ABMD Position: Q4 2022 in Review

Grimes & Company sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,014 shares — an estimated $249K sold.

Grimes & Company first reported a position in ABMD in Q2 2021 and held it in 5 quarters. The position peaked at $249K in Q3 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Grimes & Company reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Grimes & Company sold 1,014 Abiomed Inc shares in Q4 2022, an estimated $249K.
  • Grimes & Company first reported a position in Abiomed Inc in Q2 2021 and held it in 5 quarters.
  • Grimes & Company's Abiomed Inc position peaked at $249K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Grimes & Company's 13F filing for Q4 2022, filed 25 Jan 2023.